Allogeneic mesenchymal stromal cells

BIOLOGICAL2 trials

Sponsors

Ottawa Hospital Research Institute, Medical University of South Carolina

Conditions

COVID-19 PneumoniaSeptic ShockViral Pneumonia

Phase 1

Cellular Immunotherapy for Septic Shock: A Phase I Trial

CompletedNCT02421484

Ottawa Hospital Research InstituteSeptic Shock

Start: 2015-05-31End: 2018-10-30Updated: 2018-10-31

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

WithdrawnNCT05286255

Medical University of South CarolinaCOVID-19 Pneumonia, Viral Pneumonia

Start: 2024-10-01End: 2024-10-01Updated: 2024-10-30

Related Papers

Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial

BMJ Open2022-04-013 citations

A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit.

2020-11-2511 citations

Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial

American Journal of Respiratory and Critical Care Medicine2017-09-29164 citations